These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24630562)

  • 1. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.
    Kuduk SD; Skudlarek JW; Di Marco CN; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1784-9. PubMed ID: 24630562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual pyrimidine participation: efficient stereoselective synthesis of potent dual orexin receptor antagonist MK-6096.
    Chung JY; Zhong YL; Maloney KM; Reamer RA; Moore JC; Strotman H; Kalinin A; Feng R; Strotman NA; Xiang B; Yasuda N
    Org Lett; 2014 Nov; 16(22):5890-3. PubMed ID: 25365229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
    Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
    Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
    Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
    Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
    Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
    Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
    Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
    Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
    J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.
    Futamura A; Nozawa D; Araki Y; Tamura Y; Tokura S; Kawamoto H; Tokumaru Y; Kakihara S; Aoki T; Ohtake N
    Bioorg Med Chem; 2017 Oct; 25(20):5203-5215. PubMed ID: 28807572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
    Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Hoecker J; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Gatfield J; Treiber A; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1201-8. PubMed ID: 24447850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
    Mercer SP; Roecker AJ; Garson S; Reiss DR; Meacham Harrell C; Murphy KL; Bruno JG; Bednar RA; Lemaire W; Cui D; Cabalu TD; Tang C; Prueksaritanont T; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6620-4. PubMed ID: 24215892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
    Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3857-63. PubMed ID: 23719231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
    Lan Y; Chen Y; Cao X; Zhang J; Wang J; Xu X; Qiu Y; Zhang T; Liu X; Liu BF; Zhang G
    J Med Chem; 2014 Dec; 57(24):10404-23. PubMed ID: 25420090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
    Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.
    Boss C; Roch-Brisbare C; Steiner MA; Treiber A; Dietrich H; Jenck F; von Raumer M; Sifferlen T; Brotschi C; Heidmann B; Williams JT; Aissaoui H; Siegrist R; Gatfield J
    ChemMedChem; 2014 Nov; 9(11):2486-96. PubMed ID: 25147058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.
    Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M
    J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.